title: ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts.
authors.forename: Neil B
authors.initials: NB
authors.lastname: Quigley
authors.forename: Donald C
authors.initials: DC
authors.lastname: Henley
authors.forename: Roger A
authors.initials: RA
authors.lastname: Hubbard
authors.forename: Jennifer
authors.initials: J
authors.lastname: Laudadio
authors.forename: Richard D
authors.initials: RD
authors.lastname: Press
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005091:Exons / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D016254:Mutagenesis, Insertional; D010770:Phosphotransferases / Q000737:chemistry* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D014158:Transcription, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D010770:Phosphotransferases; D016044:Fusion Proteins, bcr-abl